Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Pharma
Sarepta to test Elevidys with immunosuppressive regimen
Sarepta will study its gene therapy Elevidys with the immunosuppressant sirolimus in non-ambulatory patients with Duchenne muscular dystrophy.
Zoey Becker
Nov 25, 2025 2:19pm
FDA limits Elevidys gene therapy to ambulatory Duchenne patients
Nov 14, 2025 3:20pm
Sarepta, despite key trial flop, will seek full nod for DMD meds
Nov 4, 2025 7:56am
Sarepta shares more Elevidys safety data
Aug 18, 2025 11:32am
With $1B in debts due in 2027, Sarepta weighs efficiency measures
Aug 6, 2025 5:44pm
FDA backtracks on Sarepta's gene therapy Elevidys in DMD
Jul 28, 2025 6:02pm
